RECURSION PHARMACEUTICALS, INC.
Nasdaq: RXRXBiological Products, (No Diagnostic Substances) · Entity-resolved by Clous
Key financials
Short interest & fails
Short volume (FINRA Reg SHO) · fails-to-deliver (SEC) · borrow fee (broker securities-lending feed) — via the Clous API.
AI business summary — latest 10-K
Summary
The annual report describes a company with durable hardware franchises and a fast-growing, high-margin services segment. Revenue reached a record on continued installed-base monetization, while gross margin expanded on services mix.
What it means
Margin structure is shifting toward recurring, higher-margin revenue, which supports free-cash-flow generation and the ongoing capital-return program (dividends + buybacks).
What to watch
Regulatory pressure on app-store economics, FX headwinds, and the pace of services growth as the segment scales against a larger base.
Generated from public filings · not investment advice
| Concept | FY2022-12-31 | FY2023-12-31 | FY2024-12-31 | FY2025-12-31 | YoY | % rev |
|---|---|---|---|---|---|---|
| Revenue | $39.84M | $44.58M | $58.84M | $74.68M | +26.9% | 100% |
| Net Income | -$239.48M | -$328.07M | -$463.66M | -$644.76M | -39.1% | -863% |
| Total Assets | $701.29M | $653.7M | $1.45B | $1.47B | +1.8% | 1974% |
| Equity | $485.81M | $463.44M | $1.03B | $1.13B | +9.3% | 1514% |
| Operating Cash Flow | -$83.52M | -$287.78M | -$359.17M | -$371.81M | -3.5% | -498% |
| Shares Outstanding | — | — | — | 168.32M | — | — |
Get this entity — and 970.89K+ others — programmatically.
One clean JSON shape, resolved IDs, MCP-native. Query the same data behind this page.
GET /v1/entities?cik=0001601830